Cara Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-07-02
- Employees
- 55
- Market Cap
- $19.6M
- Introduction
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Clinical Trials
36
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (35 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica
- Conditions
- PruritusNotalgia Paresthetica
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT05978063
- Locations
- 🇪🇸
Cara Therapeutics Study Site, Madrid, Spain
🇵🇱Cara Therapeutics Study Site 2, Katowice, Poland
CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients
- Conditions
- Hemodialysis
- Interventions
- Drug: CR845 0.5 mcg/kgOther: Placebo
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05533008
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Minneapolis, Minnesota, United States
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
- Conditions
- PruritusAtopic Dermatitis
- Interventions
- Drug: TCS CreamDrug: PlaceboDrug: Vehicle Cream
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 287
- Registration Number
- NCT05387707
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Morgantown, West Virginia, United States
🇺🇸Cara Therapeutics Study Site 2, Santa Monica, California, United States
CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
- Conditions
- Chronic Kidney DiseasesPruritus
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT05356403
- Locations
- 🇪🇸
Cara Therapeutics Study Site, Vitoria, Spain
🇪🇸Cara Therapeutics Study Site 2, Valencia, Spain
A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
- Conditions
- Chronic Kidney DiseasesPruritus
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 286
- Registration Number
- NCT05342623
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Hampton, Virginia, United States
🇺🇸Cara Therapeutics Study Site 2, Houston, Texas, United States
🇺🇸Cara Therapeutics Study Sites, Corsicana, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Tvardi Therapeutics Completes Merger with Cara, Advances STAT3 Inhibitor Programs for Fibrosis-Driven Diseases
Tvardi Therapeutics has completed its merger with Cara Therapeutics, creating a Nasdaq-listed company focused on developing STAT3 inhibitors for fibrosis-driven diseases, with shares trading under the ticker "TVRD."
DIAGNOS Secures $2 Million in Private Placement to Advance AI-Based Healthcare Screening Technology
DIAGNOS has successfully closed a non-brokered private placement raising CAD $2.01 million through the issuance of 6.7 million units at $0.30 per unit.